Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459720 | 0.81 | CYP11B1 (0.38) | HTR2AHTR2CCYP11B1CYP11B2EPAS1 | |
| SCHEMBL8614271 | 0.81 | CYP11B1 (0.38) | HTR2AHTR2CCYP11B1CYP11B2EPAS1 | |
| Hydrochloric Acid SCHEMBL8614165 | 0.79 | CYP11B1 (0.37) | HTR2AHTR2CCYP11B1CYP11B2EPAS1 | |
| SCHEMBL16290334 | 0.78 | ACHE (0.31) | ACHEANPEP | |
| SCHEMBL30015835 | 0.78 | IL1RN (0.32) | ACHEANPEP | |
| SCHEMBL16290348 | 0.78 | CYP11B1 (0.33) | CYP11B1CYP11B2EPAS1ANPEP | |
| SCHEMBL18710387 | 0.77 | HTR1D (0.31) | — | |
| SCHEMBL18710440 | 0.77 | HTR2A (0.31) | HTR2AHTR2C | |
| SCHEMBL16290324 | 0.75 | CA1 (0.47) | — | |
| SCHEMBL16290394 | 0.74 | LAP3 (0.34) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865663-B1 | NOVEL INDANESULFAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2865663-A1 | NOVEL INDANESULFAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | SCN1A, SCN7A, SCN2A | HTR2A 1510/4885HTR2C 849/4885CYP11B1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.